• Media Centre
  • Investor relations
  • Client area
  • Client area
  • Stewardship policy
  • Annual reports service

Form of Proxy

APPLIED DNA SCIENCES, INC.

Notes

No. Proposition For Against Abstain
1

DIRECTOR James A. Hayward

2

DIRECTOR Robert B. Catell

3

DIRECTOR Joseph D. Ceccoli

4

DIRECTOR Yacov A. Shamash

5

DIRECTOR Sanford R. Simon

6

DIRECTOR E. M. Schmalz Shaheen

7

Ratification of the appointment of CBIZ CPAs P.C. as our independent registered public accounting firm for the fiscal year ending September 30, 2025.

8

Grant of discretionary authority for 12 months to the Companys Board of Directors to amend the Companys Certificate of Incorporation, as amended, to authorize a reverse stock split of common stock, at a ratio in the range from one-for-five to one-for-fifty, with such specific ratio to be determined by the Companys Board of Directors following the Annual Meeting.

9

Approval, in accordance with Nasdaq listing rule 5635(d), of the exercisability of certain common stock purchase warrants, and the issuance of the common stock underlying such warrants, which warrants were issued in connection with an offering of securities of the Company that occurred on October 30, 2024.

10

Approval of an amendment to the Companys 2020 Equity Incentive Plan to increase the number of authorized shares of common stock reserved for issuance by 3 million shares.

11

Approval on a non-binding advisory basis of the compensation of the Companys named executive officers (the Say on Pay Proposal).

12

Approval on a non-binding advisory basis of the frequency of the stockholder vote on the compensation of the Companys named executive officers (the Say on Frequency Proposal).